MedPath

Chinese Academy of Medical Sciences

🇨🇳China
Ownership
Private, Subsidiary
Established
2004-07-08
Employees
-
Market Cap
-
Website
http://www.pinganzhengxing.com
Clinical Trials
Related News

Radiotherapy for Extracranial Oligometastatic Breast Cancer

Phase 3
Recruiting
Conditions
Breast Cancer Metastatic
Interventions
Drug: standard of care
Radiation: radiotherapy + standard of care
First Posted Date
2020-11-30
Last Posted Date
2022-01-11
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
170
Registration Number
NCT04646564
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

Wei-Fang Yang, Tai Zhou, Zhejiang, China

Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus Infection

Phase 1
Conditions
Rotavirus Infection
Interventions
Biological: Medium dosage IRV on a 0- and 28-day schedule
Biological: Low dosage IRV on a 0- and 28-day schedule
Biological: High dosage IRV on a 0- and 28-day schedule
Biological: Low dosage IRV on a 0- , 28- and 56-day schedule
Biological: High dosage IRV on a 0- , 28- and 56-day schedule
Biological: Placebo on day 0, 28
Biological: Placebo on day 0, 28, 56
Biological: Medium dosage IRV on a 0- , 28- and 56-day schedule
First Posted Date
2020-11-13
Last Posted Date
2020-12-10
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
32
Registration Number
NCT04626856
Locations
🇨🇳

Henan Provincial Center for Disease Control and Prevention, Zhenzhou, Henan, China

Online Noninvasive Assessment of Human Brain Death and Deep Coma by Near-infrared Spectroscopy

Conditions
Brain Death
Coma
Interventions
Procedure: Oxygen supply of low-high-low procedure
Procedure: Oxygen supply of high-low-high procedure
First Posted Date
2020-11-10
Last Posted Date
2020-11-10
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
75
Registration Number
NCT04623294
Locations
🇨🇳

NIRS assessment for brain death, Tianjin, Tianjin, China

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Phase 2
Conditions
Small Cell Lung Carcinoma
Interventions
First Posted Date
2020-11-09
Last Posted Date
2020-11-09
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
25
Registration Number
NCT04620837
Locations
🇨🇳

National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study

Phase 3
Conditions
Small-cell Lung Cancer
Interventions
Radiation: prophylactic cranial irradiation
First Posted Date
2020-09-02
Last Posted Date
2020-09-02
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
414
Registration Number
NCT04535739
Locations
🇨🇳

Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Prospective Study of Hypothyroidism After Radiotherapy for Breast Cancer

Completed
Conditions
Radiation Toxicity
Breast Neoplasms
Hypothyroidism
First Posted Date
2020-08-27
Last Posted Date
2020-08-27
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
729
Registration Number
NCT04528225
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma

Not Applicable
Conditions
Lymphoma
Interventions
First Posted Date
2020-08-13
Last Posted Date
2020-08-13
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
76
Registration Number
NCT04511351
Locations
🇨🇳

National Cancer Center, Cancer Hospital, Chinese Academy of Medical Scienses, Beijing, Beijing, China

Target Gene Sequencing for Advanced Stage, Relapsed or Refractory Natural Killer/T-cell Lymphoma

Completed
Conditions
Lymphoid Neoplasm
First Posted Date
2020-08-12
Last Posted Date
2020-08-12
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
26
Registration Number
NCT04509804
Locations
🇨🇳

Mei Dong, Beijing, Beijing, China

The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring

Recruiting
Conditions
Untreated Advanced NSCLC Patients
FISH Identified ALK Fusion Positive or Negative
Interventions
Drug: ALK inhibitor
First Posted Date
2020-08-05
Last Posted Date
2020-08-05
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
75
Registration Number
NCT04499794
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer

Phase 3
Conditions
Small-cell Lung Cancer
Interventions
Radiation: routine IMRT
Radiation: SIB-IMRT
First Posted Date
2020-08-05
Last Posted Date
2021-02-01
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
350
Registration Number
NCT04500145
Locations
🇨🇳

Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy